Inhibitor Therapeutics, Inc. (INTI)
USD 0.07
(14.55%)
USD 0.07
(14.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 378.84 Thousand USD | 157.58% |
| 2022 | -657.92 Thousand USD | -102.19% |
| 2021 | -325.39 Thousand USD | 69.27% |
| 2020 | -1.05 Million USD | 61.46% |
| 2019 | -2.74 Million USD | 39.8% |
| 2018 | - USD | 10.84% |
| 2017 | - USD | 27.1% |
| 2016 | - USD | -77.8% |
| 2015 | -3.94 Million USD | -0.3% |
| 2014 | -3.93 Million USD | -109.18% |
| 2013 | -1.83 Million USD | -235.76% |
| 2012 | 186.36 Thousand USD | 31.61% |
| 2011 | -819.76 Thousand USD | -240.59% |
| 2010 | -240.69 Thousand USD | 70.13% |
| 2009 | -1.23 Million USD | -117.34% |
| 2008 | -693.44 Thousand USD | 329.9% |
| 2007 | -1.92 Million USD | -1131.42% |
| 2006 | -59.5 Thousand USD | -114.3% |
| 2005 | 1.21 Million USD | 11.29% |
| 2004 | 1.05 Million USD | 39.19% |
| 2003 | 764.18 Thousand USD | 150.12% |
| 2002 | 296.34 Thousand USD | 159.17% |
| 2001 | -639.7 Thousand USD | -39413.5% |
| 2000 | 1274.00 USD | 100.1% |
| 1999 | -1.31 Million USD | 40.24% |
| 1998 | -1.89 Million USD | -266.67% |
| 1997 | -600 Thousand USD | -300.0% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -585.15 Thousand USD | 0.0% |
| 2024 Q1 | -774.82 Thousand USD | 100.0% |
| 2023 Q1 | -539.59 Thousand USD | -27.37% |
| 2023 Q3 | -664.76 Thousand USD | -1.56% |
| 2023 FY | - USD | -417.53% |
| 2023 Q4 | -1.27 Million USD | -91.54% |
| 2023 Q2 | -654.52 Thousand USD | -21.3% |
| 2022 FY | - USD | -102.19% |
| 2022 Q1 | -93.5 Thousand USD | -225.12% |
| 2022 Q3 | -69.98 Thousand USD | 1.15% |
| 2022 Q2 | -70.8 Thousand USD | 24.27% |
| 2022 Q4 | -423.63 Thousand USD | -505.31% |
| 2021 FY | - USD | 69.27% |
| 2021 Q1 | -167.75 Thousand USD | -200.97% |
| 2021 Q3 | -66.24 Thousand USD | -5.77% |
| 2021 Q2 | -62.63 Thousand USD | 62.66% |
| 2021 Q4 | -28.75 Thousand USD | 56.59% |
| 2020 Q3 | -302.77 Thousand USD | 3.89% |
| 2020 Q4 | -55.73 Thousand USD | 81.59% |
| 2020 Q2 | -315.04 Thousand USD | 18.26% |
| 2020 FY | - USD | 61.46% |
| 2020 Q1 | -385.44 Thousand USD | 39.57% |
| 2019 Q3 | -682.92 Thousand USD | -7.46% |
| 2019 Q1 | -791.6 Thousand USD | 40.46% |
| 2019 FY | - USD | 39.8% |
| 2019 Q4 | -637.87 Thousand USD | 6.6% |
| 2019 Q2 | -635.5 Thousand USD | 19.72% |
| 2018 Q4 | -1.32 Million USD | -13.1% |
| 2018 FY | - USD | 10.84% |
| 2018 Q3 | -1.17 Million USD | -32.92% |
| 2018 Q2 | -884.4 Thousand USD | 24.72% |
| 2018 Q1 | -1.17 Million USD | -29.76% |
| 2017 Q4 | -905.35 Thousand USD | -32.91% |
| 2017 FY | - USD | 27.1% |
| 2017 Q1 | -2.81 Million USD | -1.79% |
| 2017 Q3 | -681.16 Thousand USD | 5.32% |
| 2017 Q2 | -719.43 Thousand USD | 74.43% |
| 2016 FY | - USD | -77.8% |
| 2016 Q4 | -2.76 Million USD | -59.35% |
| 2016 Q3 | -1.73 Million USD | -30.38% |
| 2016 Q2 | -1.33 Million USD | -11.35% |
| 2016 Q1 | -1.19 Million USD | -15.61% |
| 2015 Q2 | -791.65 Thousand USD | 14.2% |
| 2015 Q3 | -1.2 Million USD | -51.84% |
| 2015 Q4 | -1.03 Million USD | 14.05% |
| 2015 FY | - USD | -0.3% |
| 2015 Q1 | -922.67 Thousand USD | -2.85% |
| 2014 Q4 | -897.13 Thousand USD | -21.55% |
| 2014 Q2 | -2.11 Million USD | -1031.79% |
| 2014 Q3 | -738.09 Thousand USD | 65.11% |
| 2014 FY | - USD | -109.18% |
| 2014 Q1 | -186.93 Thousand USD | 12.34% |
| 2013 Q3 | -1.29 Million USD | -308.67% |
| 2013 Q4 | -213.24 Thousand USD | 83.5% |
| 2013 Q2 | -316.25 Thousand USD | -422.35% |
| 2013 Q1 | -60.54 Thousand USD | -110.46% |
| 2013 FY | - USD | -235.76% |
| 2012 Q4 | 578.96 Thousand USD | 163.26% |
| 2012 Q3 | -915.22 Thousand USD | -721.39% |
| 2012 Q2 | -111.42 Thousand USD | 1.39% |
| 2012 Q1 | -112.98 Thousand USD | 82.42% |
| 2012 FY | - USD | 31.61% |
| 2011 Q4 | -642.55 Thousand USD | -1458.66% |
| 2011 Q3 | 47.29 Thousand USD | 126.95% |
| 2011 Q1 | -49.04 Thousand USD | -102.9% |
| 2011 Q2 | -175.45 Thousand USD | -257.73% |
| 2011 FY | - USD | -240.59% |
| 2010 Q1 | -668.43 Thousand USD | 30.4% |
| 2010 FY | - USD | 70.13% |
| 2010 Q4 | 1.69 Million USD | 430.13% |
| 2010 Q3 | -512.05 Thousand USD | 16.4% |
| 2010 Q2 | -612.47 Thousand USD | 8.37% |
| 2009 FY | - USD | -117.34% |
| 2009 Q4 | -960.41 Thousand USD | -102.31% |
| 2009 Q3 | -474.73 Thousand USD | -202.25% |
| 2009 Q2 | 464.29 Thousand USD | 181.24% |
| 2009 Q1 | 165.08 Thousand USD | -96.62% |
| 2008 FY | - USD | 329.9% |
| 2008 Q2 | 181.1 Thousand USD | 164.67% |
| 2008 Q1 | -280.05 Thousand USD | 32.61% |
| 2008 Q4 | 4.88 Million USD | 2046.74% |
| 2008 Q3 | -250.89 Thousand USD | -238.54% |
| 2007 FY | - USD | -1131.42% |
| 2007 Q3 | -1.04 Million USD | 58.16% |
| 2007 Q2 | -2.5 Million USD | -7865.99% |
| 2007 Q1 | -31.4 Thousand USD | 85.9% |
| 2007 Q4 | -415.6 Thousand USD | 60.29% |
| 2006 Q4 | -222.72 Thousand USD | -73.4% |
| 2006 Q3 | -128.45 Thousand USD | -154.08% |
| 2006 FY | - USD | -114.3% |
| 2006 Q2 | 237.52 Thousand USD | 338.64% |
| 2006 Q1 | 54.14 Thousand USD | -78.53% |
| 2005 Q2 | 437.88 Thousand USD | 1439.42% |
| 2005 Q1 | -32.69 Thousand USD | -114.01% |
| 2005 Q3 | 558.81 Thousand USD | 27.62% |
| 2005 Q4 | 252.17 Thousand USD | -54.87% |
| 2005 FY | - USD | 11.29% |
| 2004 Q1 | 273.55 Thousand USD | 37.11% |
| 2004 FY | - USD | 39.19% |
| 2004 Q3 | 307.27 Thousand USD | 28.18% |
| 2004 Q4 | 233.31 Thousand USD | -24.07% |
| 2004 Q2 | 239.72 Thousand USD | -12.37% |
| 2003 Q2 | 15.24 Thousand USD | 81.63% |
| 2003 Q1 | 91.91 Thousand USD | 165.86% |
| 2003 Q3 | 127.92 Thousand USD | 66.47% |
| 2003 FY | - USD | 150.12% |
| 2003 Q4 | 228.01 Thousand USD | -28.21% |
| 2002 FY | - USD | 159.17% |
| 2002 Q3 | 58.44 Thousand USD | 139.33% |
| 2002 Q4 | -139.55 Thousand USD | -164.52% |
| 2002 Q2 | 90.36 Thousand USD | -30.08% |
| 2002 Q1 | 129.25 Thousand USD | 132.8% |
| 2001 Q3 | -122.62 Thousand USD | -287.35% |
| 2001 Q1 | -236.92 Thousand USD | 37.04% |
| 2001 FY | - USD | -39413.5% |
| 2001 Q4 | -394.05 Thousand USD | -221.36% |
| 2001 Q2 | 65.45 Thousand USD | 127.63% |
| 2000 FY | - USD | 100.1% |
| 2000 Q4 | -376.3 Thousand USD | -412.21% |
| 2000 Q3 | -73.46 Thousand USD | -148.66% |
| 2000 Q2 | 150.98 Thousand USD | -49.68% |
| 2000 Q1 | 300.06 Thousand USD | 195.33% |
| 1999 Q3 | -178.19 Thousand USD | 50.0% |
| 1999 FY | - USD | 40.24% |
| 1999 Q2 | -400 Thousand USD | 0.0% |
| 1999 Q4 | -314.75 Thousand USD | -57.38% |
| 1999 Q1 | -400 Thousand USD | 33.33% |
| 1998 Q3 | -500 Thousand USD | 14.29% |
| 1998 Q2 | -700 Thousand USD | -75.0% |
| 1998 Q1 | -300 Thousand USD | 0.0% |
| 1998 FY | - USD | -266.67% |
| 1998 Q4 | -600 Thousand USD | 0.0% |
| 1997 FY | - USD | -300.0% |
| 1997 Q4 | -400 Thousand USD | 42.86% |
| 1997 Q3 | -700 Thousand USD | -232.17% |
| 1997 Q1 | 529.6 Thousand USD | 0.0% |
| 1997 Q2 | 529.6 Thousand USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.533% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 106.39% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.591% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 102.181% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 99.597% |
| Mesoblast Limited | -62.38 Million USD | 100.607% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 124.664% |
| Genus plc | 73.7 Million USD | 99.486% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 105.73% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 110.681% |
| Marizyme, Inc. | -34.28 Million USD | 101.105% |
| ContraFect Corporation | -64.99 Million USD | 100.583% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 104.319% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 108.37% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 127.025% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 114.326% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 116.303% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 173.129% |
| Accustem Sciences Inc. | -3.74 Million USD | 110.112% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.786% |
| EV Biologics, Inc. | -1.26 Million USD | 129.898% |
| Q BioMed Inc. | -617.62 Thousand USD | 161.339% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 89.394% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 159.905% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 116.583% |
| Biomind Labs Inc. | -1.03 Million USD | 136.619% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 96.164% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 105.29% |
| Skye Bioscience, Inc. | -13.54 Million USD | 102.796% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 125.47% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1615.376% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 109.753% |
| IMV Inc. | -35.52 Million USD | 101.066% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 102.387% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 115.142% |
| GB Sciences, Inc. | -1.41 Million USD | 126.681% |
| Alpha Cognition Inc. | -9.7 Million USD | 103.903% |
| HST Global, Inc. | -5303.00 USD | 7243.956% |
| CSL Limited | 4.78 Billion USD | 99.992% |
| Halberd Corporation | -74.27 Thousand USD | 610.028% |
| Enzolytics Inc. | -2.12 Million USD | 117.853% |
| Resverlogix Corp. | -11.74 Million USD | 103.226% |
| Affymax, Inc. | -14.29 Million USD | 102.65% |
| SYBLEU INC | -141.57 Thousand USD | 367.6% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 112.368% |
| argenx SE | -216.02 Million USD | 100.175% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.685% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 68.871% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 125.275% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | 106.198% |
| Zenith Capital Corp. | -8.6 Million USD | 104.402% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.152% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 2274.64% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 115.485% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 315.222% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 100.956% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 113.098% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 136.208% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -5534.206% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 121.648% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 119.722% |
| BioStem Technologies, Inc. | -7.55 Million USD | 105.015% |
| ONE Bio Corp. | 13.61 Million USD | 97.217% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 309.204% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 118.417% |
| Agentix Corp. | -1.37 Million USD | 127.617% |
| LadRx Corporation | 412.28 Thousand USD | 8.111% |
| Cell Source, Inc. | -4.27 Million USD | 108.867% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 203.165% |
| Regen BioPharma, Inc. | 1.46 Million USD | 74.157% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 140.434% |
| NovAccess Global Inc. | -1.03 Million USD | 136.61% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 95.721% |
| Itoco Inc. | -1.86 Million USD | 120.27% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 199.796% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 133.947% |
| Kadimastem Ltd | -2.62 Million USD | 114.436% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 258.413% |
| CytoDyn Inc. | -18.02 Million USD | 102.101% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 579.373% |
| Mobile Lads Corp. | -2.24 Million USD | 116.904% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 3197.915% |
| Qrons Inc. | -40.08 Thousand USD | 1045.196% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 178.003% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 28.172% |
| Rebus Holdings, Inc. | -951 Thousand USD | 139.836% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 135.672% |
| International Stem Cell Corporation | 202 Thousand USD | -87.547% |
| Bioxytran, Inc. | -3.82 Million USD | 109.917% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 819.688% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 115.388% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 101.056% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 941.876% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 113.837% |
| Neutra Corp. | -181.24 Thousand USD | 309.021% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 101.879% |
| PureTech Health plc | -11.62 Million USD | 103.258% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 101.879% |
| IXICO plc | -707 Thousand USD | 153.585% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 104.93% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.784% |
| CSL Limited | 4.73 Billion USD | 99.992% |
| Cellectis S.A. | -92.63 Million USD | 100.409% |